Supernus ADHD therapy meets in Phase IIb

Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) said the three highest doses of SPN-812 met the primary endpoint of significantly improving ADHD Rating Scale IV (ADHD-RS-IV) total score from baseline to week eight vs. placebo in a Phase IIb trial to treat ADHD. The company plans to start Phase III testing of the selective norepinephrine reuptake inhibitor next year.

The trial evaluated once-daily 100, 200, 300 and 400 mg doses of SPN-812 for five weeks following a three-week titration period in 222 children ages six to 12 with ADHD. The lowest dose of SPN-812 missed the primary endpoint. ...